Advanced in Glaucoma

Ken Hayashi

Hakata-ekimae, JP 
Advanced in Glaucoma
Hakata-ekimae, JP 
OverviewLocationsClinical Research

Overview

Ken Hayashi practices in Hakata-ekimae, Japan. Mr. Hayashi is rated as an Advanced expert by MediFind in the treatment of Glaucoma. His top areas of expertise are Astigmatism, Cataract, Nearsightedness, Cataract Removal, and Vitrectomy.

His clinical research consists of co-authoring 183 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles in the study of Glaucoma.

Gender
Male

Locations

Hakata-ekimae, 8120011, Japan
Other Locations
Toshima, 1710022, Japan
Fukuoka, Japan
Kawagoe, 3501122, Japan
Department Of Otolaryngology Head And Neck Surgery, Tokyo, Japan
Chuo, 3308777, Japan
Miyazaki, Japan
Kanagawa, Japan
Saga, Japan
Hayashi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3

183 Total Publications

Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464.
Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464.
Journal: The Lancet regional health. Western Pacific
Published: July 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hayashi's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile